This article is more than 5 years old. Information may no longer be current.
Mixed phase 2a results reported for Oxurion’s anti-PlGF combined with anti-VEGF
THR-317, a humanized antibody against placental growth factor, combined with ranibizumab showed no improvement in mean best corrected visual acuity compared with ranibizumab monotherapy in a phase 2a study, Oxurion announced in a press release.
The randomized, single-masked, active-controlled, multicenter study included 70 patients with diabetic macular edema who were treated with a combination of THR-317 and ranibizumab or ranibizumab and sham.
In the overall population of those treated with combination therapy, a mean increase in BCVA of 8.71 letters was observed after three monthly intravitreal injections compared with an increase of 8.18 letters in the monotherapy arm.
In patients who had poor or no response to previous anti-VEGF treatment, a mean increase of 8.08 letters was observed in the combination group compared with 6.43 letters in the monotherapy group. In patients who had a baseline BCVA of 65 letters or less, a mean increase of 11.14 letters was observed in combination therapy patients compared with 8.88 letters in monotherapy patients.
“The topline results from this exploratory phase 2 study indicate that THR-317 in combination with ranibizumab could play a role in the treatment of poor (or no) response to prior anti-VEGF and with patients with a baseline BCVA of less or equal to 65 letters,” Patrik De Haes, MD, Oxurion CEO, said in the release. “We will continue to review and analyze these data before deciding on how to best position this program as we progress our clinical-stage portfolio of next-generation therapies for the treatment of DME.”